Brief: AbbVie And Iambic Announce Collaboration To Accelerate AI-Driven Drug Discovery
21/09/2026 13:38
BRIEF-AbbVie And Iambic Announce Collaboration To Accelerate AI-Driven Drug Discovery Sept 21 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE AND IAMBIC ANNOUNCE COLLABORATION TO ACCELERATE AI-DRIVEN DRUG DISCOVERY
ABBVIE - PARTNERSHIP TO ACCELERATE SMALL MOLECULE DRUG DISCOVERY IN IMMUNOLOGY, NEUROSCIENCE, ONCOLOGY
ABBVIE - IAMBIC TO RECEIVE UPFRONT PAYMENT, MILESTONE PAYMENTS, AND TIERED ROYALTIES FROM COLLABORATION
Source text: ID:nPnc184y8a
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96